Dina Ramadane
Stock Analyst at Bank of America Securities
(1.90)
# 3,193
Out of 4,411 analysts
18
Total ratings
54.5%
Success rate
1.3%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Dina Ramadane
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BHVN Biohaven | Reiterated: Hold | $12 | $12.09 | -0.74% | 6 | May 27, 2026 | |
| VERA Vera Therapeutics | Reiterated: Buy | $66 → $65 | $33.67 | +93.05% | 6 | May 22, 2026 | |
| PROK ProKidney | Reiterated: Sell | $1 | $1.69 | -40.83% | 2 | May 18, 2026 | |
| AMLX Amylyx Pharmaceuticals | Reiterated: Buy | $22 | $15.05 | +46.18% | 2 | May 7, 2026 | |
| CPRX Catalyst Pharmaceuticals | Reiterated: Buy | $35 | $31.35 | +11.64% | 1 | Apr 27, 2026 | |
| IMVT Immunovant | Reiterated: Buy | $32 | $33.56 | -4.65% | 1 | Feb 6, 2026 |
Biohaven
May 27, 2026
Reiterated: Hold
Price Target: $12
Current: $12.09
Upside: -0.74%
Vera Therapeutics
May 22, 2026
Reiterated: Buy
Price Target: $66 → $65
Current: $33.67
Upside: +93.05%
ProKidney
May 18, 2026
Reiterated: Sell
Price Target: $1
Current: $1.69
Upside: -40.83%
Amylyx Pharmaceuticals
May 7, 2026
Reiterated: Buy
Price Target: $22
Current: $15.05
Upside: +46.18%
Catalyst Pharmaceuticals
Apr 27, 2026
Reiterated: Buy
Price Target: $35
Current: $31.35
Upside: +11.64%
Immunovant
Feb 6, 2026
Reiterated: Buy
Price Target: $32
Current: $33.56
Upside: -4.65%